Battling rare diseases is one of the most prevailing challenges of our time. According to Global Genes, scientists have uncovered around 7,000 different types, all of which affect 350 million people worldwide. However, because rare diseases are so severe and complex, finding cures is almost impossible. Healx, a biotechnology company based in England, is looking to change this by harnessing the power of machine learning and artificial intelligence. Healx is supported by the Accelerate Cambridge programme at the Entrepreneurship Centre of Cambridge Judge Business School.
Read the full article [forbes.com]